Logo Image
News
Media
Peer ExchangeCase-Based Psych PerspectivesClinical Case CollectiveClinical Forum InsightsInsightsPeers & PerspectivesPodcastsShortsSlideshowsVideos
Conferences
Conference CoverageConference Listing
Publication
Psychiatric Times
More
Job Board
CME/CE
Partners
Editorial
Resources
Between the LinesExpert PerspectivesClinical ConsultClinical ScalesInteractive ToolsLive EventsPartner PerspectivesQ&AQuizzesSeriesSpecial ReportsSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Publication
  • Job Board
  • CME/CE
  • Partners
  • Editorial
  • Resources
  • Subscribe
  • ADHD
  • Addiction & Substance Use
    • Behavioral Addictions
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Amphetamine Related Disorders
    • Substance Use Disorder
  • Alzheimer Disease & Dementia
  • Anxiety Disorders
    • Panic Disorder
  • Cannabis
  • Case Discussions
  • Comorbidity
  • Consultation-Liaison Psychiatry
    • COVID-19
  • Cultural Psychiatry
  • Drug Watch
  • Eating Disorders
  • Emergency Psychiatry
  • Ethics
  • Forensic Psychiatry
    • Munchausen Syndrome
    • Sexual Offenses
  • Integrative Psychiatry
  • Life Cycle Psychiatry
    • Postpartum Disorders
    • Geriatric Psychiatry
    • Child & Adolescent Psychiatry
  • Mental Health Awareness Month
  • Mood Disorders
    • Treatment-Resistant Depression
    • Major Depressive Disorder
    • Bipolar Disorder
  • Neuromodulation
  • Neuropsychiatry
    • Cognition
    • Dementia
    • Autism
  • Obsessive-Compulsive Disorders
  • PTSD, Trauma & Stress Disorders
    • Disaster Psychiatry
    • Trauma And Violence
    • Traumatic Stress Disorders
  • Personality Disorders
    • Compulsive Personality Disorder
    • Dependent Personality Disorder
    • Dissociative Identity Disorder
    • Histrionic Personality Disorder
    • Schizoid Personality Disorder
    • Antisocial Personality Disorder
    • Borderline Personality
  • Psychedelics & Cannabis
  • Psychiatry & Society
    • Diversity, Equity, Inclusion
    • Climate Change
    • Media & Psychiatry
  • Psychopharmacology
  • Psychosomatics
    • Delirium
    • Metabolic Disorders
    • Somatoform Disorder
  • Psychotherapy
    • Cognitive Behavioral Therapy
  • Schizophrenia/Psychosis
    • Paranoid Schizophrenia
    • Psychotic Affective Disorders
    • Schizoaffective
    • Schizophrenia Psychotic Features
    • Schizotypal Personality Disorder
    • Catatonic Schizophrenia
  • Sleep-Wake Disorders
    • Narcolepsy
    • Nocturnal Paroxysmal Dystonia
    • Sleep Deprivation
    • Sleep Wake Transition
    • Circadian Rhythm Sleep Disorders
  • Special Populations
    • Sports Psychiatry
    • Pervasive Developmental Disorder
    • LGBTQ+
    • Gender Issues
    • Military Mental Health
  • Suicide
  • Tardive Dyskinesia
  • Technology & Psychiatry
    • Digital Therapeutics
    • Artificial Intelligence
Spotlight -
Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|
Major Depressive Disorder
Advertisement

Sarra Nazem, PhD

Advertisement

Articles by Sarra Nazem, PhD

suicide risk assessment

Suicide Risk Assessment and Management: Tips for Improving Care and Outcomes

BySarra Nazem, PhD,Bridget Matarazzo, PsyD,Hal Wortzel, MD
January 31st 2019

Determining how to ensure delivery of excellent care while balancing medicolegal demands may seem to be an impossible task. When done in a collaborative way, safety planning can help the clinician better understand risk and targets for intervention.

Advertisement

Latest Updated Articles

  • suicide risk assessment
    Suicide Risk Assessment and Management: Tips for Improving Care and Outcomes

    January 31st 2019



Advertisement
Advertisement

Trending on Psychiatric Times

1

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

2

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

3

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

4

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

5

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

  • About
  • Advertise
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us